Imagine that you found a drug at a government lab that others passed over which promises to cure, not just treat, certain blood cancers. You entered into a cooperative R&D agreement where your funding doubled the lab’s budget in a critical research area while they leverage the expertise of your company. You’re a small American company taking on the big boys, with a state of the art facility hoping to be first to market with a revolutionary therapy.
{iframe}http://www.ipwatchdog.com/2017/01/03/national-cancer-institute-didnt-deserve-treatment-new-york-times/id=76353/{/iframe}